LCTX Feb 2020 2.500 call

OPR - OPR Delayed Price. Currency in USD
0.0500
0.0000 (0.00%)
As of 9:36AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.0500
Strike2.50
Expire Date2020-02-21
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume10
Open Interest323
  • Business Wire

    Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (dry AMD), have been accepted for presentation at the 2020 Association for Research in Vision and Ophthalmology (ARVO) Meeting, which will be held May 3rd through May 7th, 2020 at the Baltimore Convention Center in Baltimore, MD. The abstract presentation, entitled, "Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results", will be presented as part of the Gene Therapy and Stem cells Session on May 3rd, 2020 from 3:00PM to 4:45PM EDT by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine; Clinical Governance Board, Cincinnati Eye Institute (presentation number 865). The presentation will provide updated data from patient cohorts 1 through 4 of the clinical study and will include data on the first patients dosed with both a new subretinal delivery system as well as with a new Thaw-and-Inject (TAI) formulation of OpRegen.

  • Business Wire

    Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at NobleCon16 \- Noble Capital Markets’ Sixteenth Annual Investor Conference on February 18, 2020 at 2:30pm Eastern Time at the Hard Rock Hotel & Casino, Hollywood, Florida in Terrace Ballroom B.

  • Business Wire

    Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing Phase I/IIa clinical study of OpRegen®, the Company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD). Dry AMD is a leading cause of adult blindness in the developed world with no FDA-approved treatment options.

  • BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why
    Zacks

    BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why

    BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Business Wire

    Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of common stock of OncoCyte Corporation at a price to buyers of $2.156 per share, representing the average closing price of OncoCyte common stock over the five trading days prior to the execution of the agreement. Net proceeds from the sale were approximately $5 million. The sale is expected to close by January 9, 2020, subject to certain closing conditions. Following the completion of the sale, Lineage will own approximately 6 million shares, which represents less than 10% of OncoCyte’s outstanding common stock. Based on the closing price of OncoCyte’s common stock on January 2, 2020, the value of Lineage’s remaining OncoCyte shares following the closing is approximately $13.5 million. Lineage has agreed not to sell additional shares of OncoCyte common stock until March 17, 2020 or unless the OncoCyte common stock price closes above $3.40.

  • Should You Buy Lineage Cell Therapeutics, Inc. (LCTX)?
    Insider Monkey

    Should You Buy Lineage Cell Therapeutics, Inc. (LCTX)?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]